

## MOPEAD presented at CTAD Conference (Clinical Trials on Alzheimer's Disease) on November 4<sup>th</sup>, 2017

This year MOPEAD was at the CTAD Conference in Boston. A Focus Panel titled “Pre-screening Initiatives to Identify Individuals with Preclinical or Early Alzheimer’s disease for Clinical Trials” discussed mechanisms to identify individuals with earlier-stage disease in the general population and in primary care settings, communicate the nature of clinical research, expedite evaluation at the research site, and ensure good communication with primary care providers.

The number of clinical trials in Alzheimer’s disease has expanded dramatically in recent years (*Cummings et al. Alzheimers Res Ther 2014*). However, there has not been a commensurate increase in the number of patients identified as potential candidates for these trials, with a resulting dearth of subjects (*Fargo et al. Alzheimers Dement 2016*). This is particularly true as investigators seek to intervene earlier in the disease, including at the pre-symptomatic and mild cognitive impairment (MCI) stages. Individuals with earlier-stage disease are generally seen in primary care settings and may not self-identify, especially in the pre-symptomatic stage.

The panel participants presented the results of two initiatives that identified enriched populations of MCI and mild AD patients from the CHARIOT registry (Dr. Price) and amyloid PET imaging referrals (Dr. Rowe), with a focus on the relative merits and learnings. Dr. Boada presented MOPEAD, to examine the [four alternative strategies](#) to engage individuals at risk for AD.

Panel as follows:

**Moderator:** Jamie A Mullen, MD, AstraZeneca, Waltham MA, USA

- 1. The Funnel study: Pre-screening for MCI and mild AD patients from the CHARIOT Register**  
*Geraint J Price - Maxwell J Benjamin - Lisa K Curry - Sabrina WL Smith - Lefkos T Middleton*  
Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, UK
- 2. A prescreening study using amyloid PET to improve recruitment for early Alzheimer’s disease drug trials**  
*Christopher C Rowe, MD - Austin Health, Melbourne, Australia*
- 3. Models of Patient Engagement in Alzheimer’s Disease (MOPEAD): a European project to move Alzheimer’s disease environment towards an earlier diagnosis**  
*Mercè Boada, MD, PhD - Laura Campo - Dhaval Desai - Hans Peter Hundemer - Octavio Rodriguez-Gomez, MD - Bengt Winblad, Prof, MD, PhD - Frank Jessen, MD, PhD - Peter Jelle Visser, MD, PhD - Milica Kramberger, MD, PhD - Rafael Simó, MD, PhD - Rafael Navajo - Annette Dumas - Jean Georges, BA - David Krivec - Peggy Maguire - Derek MacKenzie*